Reports and Proceedings
Tattoo inks contain pigments and additives. According to the provisions of the German Food, Consumer Goods and Feed Code (Lebensmittel-, Bedarfsgegenstände- und Futtermittelgesetzbuch, LFGB), tattoo inks may not be used if there is any doubt as to their safety to health. Substances or mixtures for tattooing purposes are regulated in the REACH Regulation [entry 75 of Annex XVII of the REACH Regulation (Regulation (EC) No 1907/2006)]. However, there are as yet no binding criteria according to which a safety assessment of tattoo inks should be carried out. There is also a lack of suitable test methods and data for a health risk assessment. For example, little is known about adverse effects that may be associated with the injection of tattoo inks into the skin or about possible effects that may be induced in other organs. Therefore, the German Federal Institute for Risk Assessment (BfR) has developed minimum requirements for tattoo inks as well as test methods for manufacturers and distributors who are primarily responsible for the safety of their products. Therefore, the German Federal Institute for Risk Assessment (BfR) has developed minimum requirements for tattoo inks as well as test methods for manufacturers and distributors who are primarily responsible for the safety of their products. The complete opinion can be found on the BfR website: https://www.bfr.bund.de/cm/349/tattoo-inks-minimum-requirements-and-test-methods.pdf
The current gold standard for COVID-19 diagnosis is a nasal swab followed by reverse transcription polymerase chain reaction. But such tests are time consuming, requiring days before results are available. This wastes crucial time in the treatment and prevention of the disease. Recently, scientists from Korea have developed a computerized framework that can swiftly and accurately interpret chest CT scans to provide COVID-19 diagnosis in minutes, potentially changing how we tackle this disease.
- Medical Image Analysis
University of California San Diego Physics Professor Tom Murphy is among five authors of an essay, appearing in the November 2021 issue of the journal Energy Research & Social Science, that cautions current levels of worldwide economic growth, energy use and resource consumption will overshoot Earth’s finite limits.
- Energy Research & Social Science
One fifth of the global harvested area has two thirds of the global potential for mitigating cropland nitrous oxide emissions, a very powerful greenhouse gas, according to a new study led by Peking University’s College of Urban and Environmental Sciences.
- Nature Food
What if, in order to understand the social intelligence of animals, including humans, we had to study the brain at the group level and not only at rather than the individual level? This is a perspective put forward by Julia Sliwa, a CNRS researcher at the Paris Brain Institute, in the journal Science.
Accurate and near real-time data on the course and evolution of the COVID-19 pandemic have been instrumental in informing public health mitigation strategies and policy worldwide. Although many aspects of the pandemic have been tracked across numerous types of data, including rates of infection, hospitalizations and deaths, Christina Pagel and Christian Yates argue in a Perspective that the inherent biases and pitfalls in interpretation in each data source need to be recognized and accounted for. “Because choosing the right mitigation policies relies on an accurate assessment of the current state of the local epidemic, the potential ramifications of misinterpreting data are serious,” write the authors. Pagel and Yates provide an overview of the ways in which COVID-19 is currently being tracked worldwide, like through case rates, for example, and highlight the sources of potential bias inherent within related data. What’s more, the authors discuss the data not currently being reliably captured, particularly incidences of Long Covid and breakthrough cases among vaccinated individuals. According to Pagel and Yates, using all available data to quantify the pandemic is crucial to address it, and relying too much on a single data source or a limited selection of aggregated data risks misunderstanding the state of the epidemic.
The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, which recently expanded its focus to include evaluating outpatient treatment for COVID-19, today announced that the external data and safety monitoring board (DSMB) has recommended that SNG001, an inhaled formulation of interferon beta, advance to phase 3 in the ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies Trial (ACTG A5401). SNG001 is the third agent to graduate to phase 3 in ACTIV-2, which is evaluating multiple investigational agents to treat early, symptomatic COVID-19 in non-hospitalized individuals. For more information about the trial, please visit the study website.
Armed with a novel strategy they developed for bolstering the body’s immune response, scientists at Albert Einstein College of Medicine have successfully suppressed HIV infections in mice—offering a path to a functional cure for HIV and other chronic viral infections. Their findings were published today in the Journal of Clinical Investigation.
- Journal of Clinical Investigation
Presented at FiO LS, Toshiba Europe Limited and University of Leeds researchers have developed a method of secure quantum communication that achieves transmission over long distances, with the potential to overcome present limitations in transmitting quantum-encrypted information.
- Frontiers in Optics + Laser Science (FiO LS)
The first investigational transplantation of a genetically engineered, nonhuman kidney to a human body was recently completed at NYU Langone Health—marking a major step forward in potentially utilizing an alternative supply of organs for people facing life-threatening disease.
Nations the world over are guilty of “policy inertia” when it comes to supporting young people who lost work or will struggle to enter the labour market as a result of the pandemic, according to new University of Cambridge research.